Floatz logo

Cetuximab

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma

National Cancer Institute (NCI)monoclonal_antibodyPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma cohort.

Asset / SponsorPhaseRating
(18F)FPPRGD2
Sanjiv Sam Gambhir
Phase 1/2CCC
Pembrolizumab
Advaxis, Inc.
Phase 1/2CCC
FLUDEOXYGLUCOSE
Sanjiv Sam Gambhir
Phase 1/2CCC
Adxs-503
Advaxis, Inc.
Phase 1/2CCC
(11-L-THREONINE, 29-L-ARGININE)LACTOFERRIN(HUMAN) PRODUCED BY ASPERGILLUS NIGER VAR. AWAMORI
Stanford University
Phase 1CC

Same molecule, other indications

Cetuximab is also rated in:

colon adenocarcinomaDormant
BB
Indicative ·
70 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
70 / 100
View asset →
rectal carcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →